Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting an estimated 80% of pregnant women.1 Because the withdrawal of Bendectin (delayed release doxylamine 10 mg-pyridoxine 10 mg; WMS Merrell Dow, Cincinnati, OH) from the US market in 1983, American women did not have access to a Food and Drug Administration (FDA)-approved drug for NVP for 30 years, until the same drug combination (under the trade name Diclegis; Duchesnay Inc., Blainville, Canada) was approved by the FDA in April 2013.2 The withdrawal of Bendectin from the US left American women without an FDA-approved drug for NVP and was associated with a 3-fold increased risk of hospitalization of women for the severe forms of this condition.3